Business Wire

CRESTBRIDGE

14.12.2020 15:32:17 CET | Business Wire | Press release

Share
Crestbridge Expand US Offer With Acquisition in New Jersey

Crestbridge, the agile alternative for private equity and real estate administration solutions, has announced that it intends to acquire New Jersey based Ovation Fund Services. Ovation is a provider of fund administration, accounting and reporting services to US domestic private equity and real estate funds. The acquisition complements Crestbridge’s core service offering in both asset classes.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201214005445/en/

Ovation will become part of the Crestbridge brand from 31 December 2020 and is the business’ seventh office. All Ovation employees will become members of the global Crestbridge team, ensuring continuity of client service and working with the wider Crestbridge Group to continue to grow and develop the current services offering.

The acquisition substantially expands Crestbridge’s presence in the US, where it already has an office in New York, and its ability to service private equity and real estate funds. It also enhances the multi-jurisdiction proposition to its client base as the new office complements Crestbridge’s existing network of offices in London, Luxembourg, Bahrain, the Cayman Islands, New York and Jersey (Channel Islands), providing access to its international team of experts for North American clients.

Commenting on the new office, Paul Perris, Chief Commercial Officer of the Crestbridge Group said: “This is another significant achievement in delivering our global expansion strategy and widening access to our solutions for private equity and real estate fund managers. In particular, this provides North American based clients access to European investment markets and turnkey solutions, which continues to be an increasingly strong trend, as well as supporting inward investment into North America. We are very much looking forward to supporting our global client base and helping facilitate their continued success.”

The New Jersey office will be headed by Scot Hadley, Ovation’s founder, who has over 23 years’ experience growing businesses and building long-term relationships within the private equity and real estate industry in the US and beyond. Scot established Ovation nearly four years ago, building a successful business with a loyal customer base. Prior to establishing Ovation, Scot spent 18 years of his career at Paladin Realty Partners, an institutional real estate fund manager, where he was one of ten founding members of the firm.

Scot commented: “We believe that bringing the quality and breadth of Crestbridge’s global capabilities together with our focus on the US markets is very attractive to current and prospective clients. Access to a global team with the same high standards as ours will be a huge benefit and we’re excited by the opportunities.”

The office is based in Morristown, New Jersey. The financial terms of the acquisition are not being disclosed.

This latest acquisition in North America also follows the announcement of ‘Crestbridge Fiduciary LLC’, created to better support families with US-based interests. This joint venture with Wyoming-based Willow Street was formed in response to exceptional client demand for Family Office Services and consolidates Crestbridge’s global expertise with Willow Street’s in-depth trust and fiduciary capability and high-calibre client base.

Ends.

Notes to editors

  • We are a leading global administration, management & corporate governance solutions business.
  • We provide a broad range of outsourced fiduciary, administrative, accounting and compliance services globally – our expertise spans services, asset classes and jurisdictions. Since 1998, we have been putting our insight and experience to work for clients who include leading corporations, sovereign wealth funds, investor groups, asset managers and ultra-high net worth families.
  • Crestbridge employs over 350 people and has six international offices: Bahrain, Cayman Jersey, London, Luxembourg and New York.
  • For our regulatory information please see here for more details.

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

OM Pharma to Unveil the Largest Multi-Country Real-World Evidence Study on Broncho‑Vaxom® (OM‑85) for RTI Prevention at EAACI 202614.6.2026 10:00:00 CEST | Press release

REACH study met its first primary endpoint, showing that Broncho‑Vaxom® (OM‑85) was associated with a 28-38% reduction in respiratory tract infection rates at 12 months and 29-41% reduction at 24 months, comparing post-treatment versus pre-treatment initiation.1 The reduction was observed regardless of the frequency of respiratory tract infections in the previous year (1-3, >3) and across age subgroups (1-5, 6-11, 12-17, 18-64, >64 years).1 By reflecting everyday clinical practice and capturing episodes that necessitated a visit to the doctor, these extensive data offer critical new evidence of the therapy’s long-term relevance for patients suffering from recurrent respiratory tract infections. Evaluating a vast cohort of more than 15,790 paediatric, adolescent, adult and elderly patients in China, Italy, and Belgium, REACH represents the largest and only multi-country real-world evidence study to date for Broncho-Vaxom®.1,2 The study cohort includes patients with different co-morbidit

Incyte Announces New Positive Data at EHA 2026 Showed INCA033989 Achieved Rapid, Robust and Sustained Clinical and Molecular Responses and Was Well Tolerated in Patients with Myelofibrosis and Essential Thrombocythemia13.6.2026 17:15:00 CEST | Press release

In myelofibrosis (MF), INCA033989 delivered rapid and durable clinical benefits including meaningful spleen volume reductions, symptom improvement and anemia responses, both as a monotherapy and in combination with ruxolitinibIn essential thrombocythemia (ET), 87% of patients achieved a hematologic response, including 70% complete responses; responses were rapid (median ~2 weeks to a durable complete hematologic response) and durable (median response duration of 23 weeks)Across MF and ET, INCA033989 consistently reduced mutant CALR (mutCALR) variant allele frequency (VAF) in most evaluable patients, with reductions correlating with clinical responses and supporting its potential for disease modificationFirst-in-class mutCALR-targeted antibody shows potential to modify disease biology in both MF and ETINCA033989 demonstrated a favorable and manageable safety profile with no dose-limiting toxicities, with most patients with MF and ET continuing treatment Incyte (Nasdaq:INCY) today announ

Results from Incyte’s Pivotal Phase 3 frontMIND Trial of Tafasitamab (Monjuvi®/Minjuvi®) Combination Presented at the 2026 European Hematology Association (EHA) Congress Plenary Showed Prolonged Progression Free Survival13.6.2026 12:00:00 CEST | Press release

- frontMIND study evaluating tafasitamab (Monjuvi®/Minjuvi®) in patients with previously untreated high-risk diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL) selected for the prestigious Plenary Abstracts Session at EHA 2026 - Results showed tafasitamab and lenalidomide plus R-CHOP (Tafa-Len-R-CHOP) significantly prolonged progression-free survival (PFS), reducing risk of disease progression or death by 25% - Positive trends toward PFS benefit with Tafa-Len-R-CHOP were observed acrossprespecified subgroups, including in patients with centrally confirmed lymphoma subtypes and both cell-of-origin (COO) molecular subtypes - The frontMIND data support global regulatory applications for tafasitamab and lenalidomide in addition to R-CHOP for previously untreated DLBCL and HGBL Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®), a humanized Fc-modified c

Charlotte Tilbury awarded CBE in the King’s Birthday Honours 202612.6.2026 23:31:00 CEST | Press release

Charlotte Tilbury CBE, sole Founder, President, Chairman and Chief Creative Officer of Charlotte Tilbury Beauty, has been awarded a Commander of the Order of the British Empire (CBE) in the King’s Birthday Honours 2026 for services to the beauty and cosmetics industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612679101/en/ Charlotte Tilbury, founder, president, chairman and chief creative officer of Charlotte Tilbury Beauty, who has been awarded a CBE (Commander of the Order of the British Empire) in 2026 for services to the beauty industry and entrepreneurship. (Photo: Charlotte Tilbury team) This honour recognises Charlotte’s contribution to leading and building Britain’s most successful global beauty brand. She has played a defining role in revolutionising the beauty industry and driving economic growth of the UK beauty sector, which has expanded from approximately £17bn in 2013 to over £31bn today. Charlotte Til

IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors12.6.2026 18:36:00 CEST | Press release

Venneman brings more than 30 years of digital transformation, AI, and enterprise technology experience as IQM prepares for its planned Nasdaq listing IQM Quantum Computers, the global leader in superconducting quantum computers, today announced the appointment of Barbara Venneman to its Board of Directors. Venneman deepens the Board's expertise in digital transformation, enterprise technology commercialization, and global business scaling as IQM expands its commercial footprint worldwide. Additionally, CEO and Co-founder Jan Goetz will replace Co-founder Juha Vartiainen as the Founder representative on the IQM Board. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612650938/en/ IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors Ms. Venneman joins the IQM Board of Directors following a distinguished career at the intersection of advanced technology, s

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye